OncLive TV

Alessandro A. Viansone, MD, notes how the DESTINY-Breast11 trial could support a move away from anthracycline-based therapy in HER2-positive breast cancer.

Rafael Fonseca, MD, discusses how FISH, NGS, and minimal residual disease testing guide risk stratification and treatment in multiple myeloma.

Daniel Boiarsky, MD, discusses tumor-associated macrophages and CD24 expression in patients with metastatic NSCLC.

Erman Akkus, MD, discusses how oncologists can weigh cross-trial comparisons and reach practical second-line decisions in advanced HCC.

Erman Akkus, MD, discusses why second-line treatment in advanced hepatocellular carcinoma remains undefined and how reconstructed patient data can help fill it.

Lyudmila A. Bazhenova, MD, discusses the current state and future direction of antibody-drug conjugate development in lung cancer.

Ian M. Thompson Jr, MD, MBA, discusses the potential role of 5-ARIs such as finasteride in prostate cancer.

Adam D. Cohen, MD, discusses future research directions for cevostamab in relapsed/refractory multiple myeloma.

Adam M. Brufsky, MD, PhD, discusses the FDA approval of gedatolisib/fulvestrant/palbociclib for PIK3CA wild-type hormone receptor–positive breast cancer.

John N. Allan, MD, discusses data for fixed-duration regimens in chronic lymphocytic leukemia and their respective nuances.

Michael Wong, MD, PhD, FRPC, discusses the FDA accelerated approval of vusolimogene oderparepvec-wtpg plus nivolumab in melanoma.

Jacob Stephen Thomas, MD, discusses safety data with ipatasertib plus pembrolizumab in metastatic HNSCC.

Michael J. Morris, MD, discusses the significance of the FDA approval of lutetium Lu 177 vipivotide tetraxetan plus an ARPI in PSMA+ mHSPC.

Narjust Florez, MD, discusses how the agenda for the Bridging the Gaps in Lung Cancer meeting evolves year to year based on emerging data and community feedback.

Noura Choudhury, MD, discusses how resistance mechanisms to tarlatamab-dlle could inform sequencing decisions in small cell lung cancer.

Jonathan Wesley Riess, MD, MS, discusses the evolving landscape of KRAS inhibitors, including the distinction between KRAS(OFF) and (ON) inhibitors.

Edward S. Kim, MD, MBA, discusses the purpose and value of the Bridging the Gaps in Lung Cancer meeting.

Erin Mulvey, MD, discusses real-world time to treatment discontinuation data for first-line zanubrutinib compared with other BTK inhibitors in CLL.

Adam D. Cohen, MD, discusses phase 1 efficacy data for cevostamab in relapsed/refractory multiple myeloma.

Adam D. Cohen, MD, discusses the potential role of FcRH5 as a target and the ongoing investigation of cevostamab in multiple myeloma.

Renata Ferrarotto, MD, discusses the biologic rationale for and interim findings from a phase 1 study of Emi-Le in patients with aggressive ACC.

Midhun Malla, MD, discusses specific biomarkers that are crucial for GI cancer management and how to interpret them.

Sara A. Hurvitz, MD, FACP, discusses the mechanism of action of evorpacept and data with the agent in pretreated HER2-positive metastatic breast cancer.

Toni K. Choueiri, MD, discusses safety data from LITESPARK-022 in ccRCC.

Matthew Galsky, MD, discusses data from the phase 3 KEYNOTE-B15/EV-304 study in MIBC.

Shimoli Barot, MD, highlights the role of maintenance palbociclib plus trastuzumab, pertuzumab, and endocrine therapy in HER2-positive breast cancer.

Sara M. Tolaney, MD, MPH, discusses research inspired by an analysis of first-line T-DXd plus pertuzumab in HER2-positive metastatic breast cancer.

Hamza Hashmi, MD, outlines considerations for identifying patients with early relapsed/refractory multiple myeloma as candidates for CAR T-cell therapy.

Angeles Alvarez Secord, MD, MHSc, discusses the rationale behind the phase 1/2 BEHOLD-2 trial evaluating mocertatug rezetecan plus dostarlimab in endometrial cancer.

Leonard J. Appleman, MD, PhD, discusses prior data with SYNC-T Therapy SV-102 and the ongoing LEGION-100 study in prostate cancer.